Advertisement

Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids

  • S.D. Quinn
    Correspondence
    Corresponding author. Tel.: +44 2033126666.
    Affiliations
    Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +44 7796 284 834/2033126666; fax: +44 20331 21123.
    J. Vedelago
    Footnotes
    1 Tel.: +44 7796 284 834/2033126666; fax: +44 20331 21123.
    Affiliations
    Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom
    Search for articles by this author
  • Author Footnotes
    2 Tel.: +44 2033126666.
    W. Gedroyc
    Footnotes
    2 Tel.: +44 2033126666.
    Affiliations
    Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom
    Search for articles by this author
  • Author Footnotes
    2 Tel.: +44 2033126666.
    L. Regan
    Footnotes
    2 Tel.: +44 2033126666.
    Affiliations
    Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +44 7796 284 834/2033126666; fax: +44 20331 21123.
    2 Tel.: +44 2033126666.
Published:October 06, 2014DOI:https://doi.org/10.1016/j.ejogrb.2014.09.039

      Abstract

      Objective

      To examine the safety and re-intervention rates following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids at 5 years. To assess how the non-perfused volume (NPV), fibroid signal intensity and use of gonadotrophin-releasing hormone analogues (GnRHa) affect the re-intervention rates.

      Study design

      Cohort study of women undergoing MRgFUS for treatment of their uterine fibroids between 2003 and 2010.

      Results

      Of 280 women undergoing MRgFUS the rate of minor complications was 3.9% and there were 3 serious complications (1.1%) including one skin burn, a fibroid expulsion and one case of persistent neuropathy. The NPVs achieved following MRgFUS have increased as the experience with this treatment has grown. In a 5-year follow-up study of 162 women, the overall re-intervention rate was 58.64%, but in those treatments with greater than 50% NPV the re-intervention rate was 50%.

      Conclusion

      MRgFUS treatment of uterine fibroids is a safe treatment for uterine fibroids. The re-intervention rate at 5 years is high, but the improvements in NPVs achieved may further improve the long term results.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Stewart E.A.
        • Gedroyc W.M.
        • Tempany C.M.
        • et al.
        Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique.
        Am J Obstet Gynecol. 2003; 189: 48-54
        • Rabinovici J.
        • Inbar Y.
        • Eylon S.C.
        • et al.
        Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report.
        Hum Reprod. 2006; 21: 1255-1259
        • Rabinovici J.
        • David M.
        • Fukunishi H.
        • et al.
        Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids.
        Fertil Steril. 2010; 93: 199-209
        • Funaki K.
        • Fukunishi H.
        • Sawada K.
        Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month follow-up.
        Ultrasound Obstet Gynecol. 2009; 34: 584-589
        • Taran F.A.
        • Tempany C.M.
        • Regan L.
        • et al.
        Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas.
        Ultrasound Obstet Gynecol. 2009; 34: 572-578
        • Rabinovici J.
        • Inbar Y.
        • Revel A.
        • et al.
        Clinical improvement and shrinkage of uterine fibroids after thermal ablation by magnetic resonance-guided focused ultrasound surgery.
        Ultrasound Obstet Gynecol. 2007; 30: 771-777
        • Zaher S.
        • Gedroyc W.M.
        • Regan L.
        Patient suitability for magnetic resonance guided focused ultrasound surgery of uterine fibroids.
        Eur J Obstet Gynecol Reprod Biol. 2009; 143: 98-102
        • Froeling V.
        • Meckelburg K.
        • Schreiter N.F.
        • et al.
        Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results.
        Eur J Radiol. 2013; 82: 2265-2269
        • Okada A.
        • Morita Y.
        • Fukunishi H.
        • et al.
        Non-invasive magnetic resonance-guided focused ultrasound treatment of uterine fibroids in a large Japanese population: impact of the learning curve on patient outcome.
        Ultrasound Obstet Gynecol. 2009; 34: 579-583
        • Spies J.B.
        • Coyne K.
        • Guaou Guaou N.
        • et al.
        The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.
        Obstet Gynecol. 2002; 99: 290-300
        • Quinn S.D.
        • Vedelago J.
        • Kashef E.
        • et al.
        Measurement of uterine fibroid volume: a comparative accuracy and validation of methods study.
        Eur J Obstet Gynecol Reprod Biol. 2013; 171: 161-165
        • Hosmer D.W.
        • Hosmer T.
        • Le Cessie S.
        • et al.
        A comparison of goodness-of-fit tests for the logistic regression model.
        Stat Med. 1997; 16: 965-980
      1. R: A language and environment for statistical computing [program].
        R Foundation for Statistical Computing, Vienna, Austria2012
        • Yamashita Y.
        • Torashima M.
        • Takahashi M.
        • et al.
        Hyperintense uterine leiomyoma at T2-weighted MR imaging: differentiation with dynamic enhanced MR imaging and clinical implications.
        Radiology. 1993; 189: 721-725
        • Stewart E.A.
        • Rabinovici J.
        • Tempany C.M.
        • et al.
        Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids.
        Fertil Steril. 2006; 85: 22-29
        • Stewart E.A.
        • Gostout B.
        • Rabinovici J.
        • et al.
        Sustained relief of leiomyoma symptoms by using focused ultrasound surgery.
        Obstet Gynecol. 2007; 110: 279-287
        • Toor S.S.
        • Tan K.T.
        • Simons M.E.
        • et al.
        Clinical failure after uterine artery embolization: evaluation of patient and MR imaging characteristics.
        J Vasc Interv Radiol. 2008; 19: 662-667
        • Taran F.A.
        • Hesley G.K.
        • Gorny K.R.
        • et al.
        What factors currently limit magnetic resonance-guided focused ultrasound of leiomyomas? A survey conducted at the first international symposium devoted to clinical magnetic resonance-guided focused ultrasound.
        Fertil Steril. 2010; 94: 331-334
        • Smart O.C.
        • Hindley J.T.
        • Regan L.
        • et al.
        Magnetic resonance guided focused ultrasound surgery of uterine fibroids – the tissue effects of GnRH agonist pre-treatment.
        Eur J Radiol. 2006; 59: 163-167
        • Quinn S.
        • Vedelago J.
        • Regan L.
        • Gedroyc W.M.
        Safety and treatment volumes achieved following new developments to the magnetic resonance guided focused ultrasound system in the treatment of uterine fibroids: a cohort study.
        J Ther Ultrasound. 2013; 1: 20
        • Trumm C.G.
        • Stahl R.
        • Clevert D.A.
        • et al.
        Magnetic resonance imaging-guided focused ultrasound treatment of symptomatic uterine fibroids: impact of technology advancement on ablation volumes in 115 patients.
        Invest Radiol. 2013; 48: 359-365
        • Gorny K.R.
        • Borah B.J.
        • Brown D.L.
        • Woodrum D.A.
        • Stewart E.A.
        • Hesley G.K.
        Incidence of additional treatments in women treated with MR-guided focused US for symptomatic uterine fibroids: review of 138 patients with an average follow-up of 2.8 years.
        J Vasc Interv Radiol. 2014; 25: 1506-1512